Intent to sole source for BEST 1 Bridge Contract to Acumen, LLC

The FDA intends to award a sole source contract to Acumen, LLC for the BEST 1 Bridge Contract. The purpose of this acquisition is to ensure uninterrupted management and coordination of activities across the BEST distributed data network and multiple data partners, maintain analytic capacity and capabilities, and avoid costly delays and/or disruptions in mission-critical operations. The contract will support the coordinating center for the Biologics Effectiveness and Safety (BEST) Initiative, which serves as the central hub for managing all aspects of the program. The key responsibilities of the contract include program management, technical infrastructure, analytical capabilities, scientific support, and administrative oversight. Some key points about this opportunity include: • The contract is a continuation of services currently being performed under IDIQ: HHSF223201810020I and Task Order: HHSF223201810020I / 75F40123F19005. • The current period of performance ends on 9/29/2026 with approximately $8,000,000.00 obligated to date. • The incumbent was competitively awarded the contract. • The contract supports the coordinating center for the Biologics Effectiveness and Safety (BEST) Initiative. • The coordinating center serves as the central hub for managing all aspects of the program.